Literature DB >> 16909207

The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells.

P Massi1, A Vaccani, S Bianchessi, B Costa, P Macchi, D Parolaro.   

Abstract

Recently, we have shown that the non-psychoactive cannabinoid compound cannabidiol (CBD) induces apoptosis of glioma cells in vitro and tumor regression in vivo. The present study investigated a possible involvement of caspase activation and reactive oxygen species (ROS) induction in the apoptotic effect of CBD. CBD produced a gradual, time-dependent activation of caspase-3, which preceded the appearance of apoptotic death. In addiction, release of cytochrome c and caspase-9 and caspase-8 activation were detected. The exposure to CBD caused in glioma cells an early production of ROS, depletion of intracellular glutathione and increase activity of glutathione reductase and glutathione peroxidase enzymes. Under the same experimental condition, CBD did not impair primary glia. Thus, we found a different sensitivity to the anti-proliferative effect of CBD in human glioma cells and non-transformed cells that appears closely related to a selective ability of CBD in inducing ROS production and caspase activation in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16909207     DOI: 10.1007/s00018-006-6156-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  58 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Cannabidiol inhibits angiogenesis by multiple mechanisms.

Authors:  M Solinas; P Massi; A R Cantelmo; M G Cattaneo; R Cammarota; D Bartolini; V Cinquina; M Valenti; L M Vicentini; D M Noonan; A Albini; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 3.  Cannabidiol as potential anticancer drug.

Authors:  Paola Massi; Marta Solinas; Valentina Cinquina; Daniela Parolaro
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 4.  Towards the use of cannabinoids as antitumour agents.

Authors:  Guillermo Velasco; Cristina Sánchez; Manuel Guzmán
Journal:  Nat Rev Cancer       Date:  2012-05-04       Impact factor: 60.716

Review 5.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

6.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

7.  Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Authors:  Jahan P Marcu; Rigel T Christian; Darryl Lau; Anne J Zielinski; Maxx P Horowitz; Jasmine Lee; Arash Pakdel; Juanita Allison; Chandani Limbad; Dan H Moore; Garret L Yount; Pierre-Yves Desprez; Sean D McAllister
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

8.  Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture.

Authors:  Liting Deng; Lindsay Ng; Tatsuya Ozawa; Nephi Stella
Journal:  J Pharmacol Exp Ther       Date:  2016-11-07       Impact factor: 4.030

9.  The influence of biomechanical properties and cannabinoids on tumor invasion.

Authors:  Tim Hohmann; Urszula Grabiec; Chalid Ghadban; Kerstin Feese; Faramarz Dehghani
Journal:  Cell Adh Migr       Date:  2016-05-05       Impact factor: 3.405

10.  The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas.

Authors:  Eiron Cudaback; William Marrs; Thomas Moeller; Nephi Stella
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.